Yinhu Qingwen Granula
Phase 1Small molecule
Yinhu Qingwen Granula is one of 29 small molecule programs targeting Viral Pneumonia. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Nexavar
BayerPreclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Benadryl
PParkedale
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Yinhu Qingwen Granula
ZZhong Wang
Phase 1
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Preclinical
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yinhu Qingwen Granula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- ZZhong Wang